Novavax, Inc (NVAX) plunged -5.52 in the last month: It’s impossible to believe the numbers

On Monday, Novavax, Inc (NASDAQ: NVAX) was -5.52% drop from the session before settling in for the closing price of $8.33. A 52-week range for NVAX has been $3.81 – $23.86.

Annual sales at Healthcare sector company grew by 516.28% over the past five years. When this article was written, the company’s average yearly earnings per share was at 72.71%. With a float of $146.74 million, this company’s outstanding shares have now reached $160.42 million.

Let’s look at the performance matrix of the company that is accounted for 952 employees. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.

Novavax, Inc (NVAX) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 8.77%, while institutional ownership is 59.82%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.

Novavax, Inc (NVAX) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.4 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 72.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 79.89% during the next five years compared to 25.88% growth over the previous five years of trading.

Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators

You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.86.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach 0.75 in one year’s time.

Technical Analysis of Novavax, Inc (NVAX)

Novavax, Inc (NASDAQ: NVAX) saw its 5-day average volume 6.71 million, a positive change from its year-to-date volume of 4.72 million. As of the previous 9 days, the stock’s Stochastic %D was 47.20%. Additionally, its Average True Range was 0.63.

During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 15.22%, which indicates a significant decrease from 52.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.11% in the past 14 days, which was higher than the 75.19% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.52, while its 200-day Moving Average is $11.35. Nevertheless, the first resistance level for the watch stands at $8.41 in the near term. At $8.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.26. If the price goes on to break the first support level at $7.56, it is likely to go to the next support level at $7.24. Assuming the price breaks the second support level, the third support level stands at $6.71.

Novavax, Inc (NASDAQ: NVAX) Key Stats

There are 160,185K outstanding shares of the company, which has a market capitalization of 1.27 billion. As of now, sales total 983,710 K while income totals -545,060 K. Its latest quarter income was 84,510 K while its last quarter net income were -121,300 K.